RT Journal Article
SR Electronic
A1 Vinall, Maria
T1 DCV/ASV/BCV Improves Sustained Viral Response in Patients with Chronic HCV GT-1 Infection and Compensated Cirrhosis: UNITY-2 Results
JF MD Conference Express
YR 2014
FD SAGE Publications
VO 14
IS 48
SP 11
OP 12
DO 10.1177/155989771448005
UL http://mdc.sagepub.com/content/14/48/11.abstract
AB This article presents data indicating that treatment with an all-oral fixed-dose combination of daclatasvir/asunaprevir/beclabuvir with or without the addition of ribavirin is associated with high rates of sustained viral response to treatment 12 weeks after therapy in patients with chronic compensated cirrhosis and hepatitis C virus genotype 1 infection.